Global Entrectinib Market Research Report 2022

Entrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well as ROS1 and ALK, with high potency and selectivity. RXDX-101 has demonstrated potent pharmacological activity in preclinical studies and has the potential to be first-in-class against the Trk family of kinases. PXDX-101 has been well tolerated in patients with advanced solid tumors. PXDX-101 is currently in clinical trials, and is being developed by Ignyta.
Due to the COVID-19 pandemic, the global Entrectinib market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Entrectinib market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Entrectinib landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
0.99 accounting for % of the Entrectinib global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Anaplastic Lymphoma segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Entrectinib include BOCSCI, APExBIO Technology, Cayman Chemical, ChemScence, Crysdot, Medical Isotopes, TargetMol Chemicals, Toronto Research Chemicals and Beijing Jingming Biotechnology, etc. In terms of revenue, the global 3 largest players have a % market share of Entrectinib in 2021.
This report focuses on Entrectinib volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Entrectinib market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Entrectinib Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Purity and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Purity
0.99
0.98
Segment by Application
Anaplastic Lymphoma
C-ros Oncogene
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
BOCSCI
APExBIO Technology
Cayman Chemical
ChemScence
Crysdot
Medical Isotopes
TargetMol Chemicals
Toronto Research Chemicals
Beijing Jingming Biotechnology
Cool Pharm
Shanghai Lollane Biological Technology
Shanghai Macklin Biochemical
Shanghai Muse Health Tech
ATK Chemical
Shanghai Send Pharmaceutical Technology
Shanghai Yuanye Bio-Technology
Wuhan Sun-Shine Bio-Technology